Skip to content

Evaluation of the Effectiveness of the Self-developed Pulmonary Lobar Ventilation Detector

Evaluation of the Effectiveness of the Self-developed Pulmonary Lobar Ventilation Detector

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05799040
Enrollment
40
Registered
2023-04-05
Start date
2023-10-26
Completion date
2024-12-31
Last updated
2024-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Brief summary

The goal of observational study is to Evaluation of the effectiveness of the self-developed pulmonary lobar ventilation detector in Chronic Obstructive Pulmonary Disease. The main question it aims to answer are:Evaluation of the effectiveness of the self-developed pulmonary lobar ventilation detector. Participants will use the self-developed pulmonary lobar ventilation detector and the imported Chartis detection system to evaluate the target pulmonary lobar collateral ventilation.

Interventions

DEVICESelf-developed pulmonary lobar ventilation detector

The participants would evaluated by the self-developed pulmonary lobar ventilation detector.

DEVICEChartis detection system

The participants would evaluated by the Chartis detection system.

Sponsors

China-Japan Friendship Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Patients with chronic obstructive pulmonary disease who meet the GOLD diagnostic criteria * FEV1 ≤ 45% pred and FEV1/FVC\<70% * TLC\>100% pred and RV\>175% pred * CAT≥18 * \>50% of emphysema destruction * Smoking prohibition\>6 months * Sign the informed consent form

Exclusion criteria

* PaCO2\>8.0 kPa, or PaO2\<6.0 kPa * 6-minute walking test\<160m * Obvious chronic bronchitis, bronchiectasis or other infectious lung diseases * Three hospitalizations due to pulmonary infection in the past 12 months before the baseline assessment * Previous lobectomy, LVRS or lung transplantation * LVEF\<45% and or RVSP\>50mmHg * Anticoagulant therapy that cannot be stopped before surgery * The patient has obvious immune deficiency * Participated in other lung drug studies within 30 days before this study * Pulmonary nodules requiring intervention * Any disease or condition that interferes with the completion of the initial or subsequent assessment

Design outcomes

Primary

MeasureTime frameDescription
Therapeutic effect of lung volume reduction surgery1 month after bronchoscopic valve lung volume reductionLung CT
the integrity of interlobar fissureBefore bronchoscopic valve lung volume reductionUse the self-developed pulmonary lobar ventilation detector and the imported Chartis detection system to evaluate the target pulmonary lobar collateral ventilation

Countries

China

Contacts

Primary ContactMingming Deng, MD
isdeng1017@163.com86 18801336854

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026